Ahn MJ, Kim HR, Yang JCH, Han JY, et al. Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study. Clin Lung Cancer 2022 Jul 21. pii: S1525-7304(22)00152.
PMID: 36038416